Pertuzumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Pertuzumab
- Pertuzumab: From HER2-Positive Breast Cancer to Normal Breast-Like Subtype of Breast Carcinoma
Using no additional skill — this is a direct content-generation task with an already fully specified template; I’ll follow it exactly against the supplied Evidence Pack.
A few data-fidelity notes before the report: predicted_indications[0] is “normal breast-like subtype of breast carcinoma”, which per the pack’s own repurposing_rationale is flagged as a likely TxGNN over-generalization artifact (L4/Hold), not the strongest candidate in the pack (ranks 2–3 have L1/Proceed-with-Guardrails evidence, but those are PR-status stratifications of Pertuzumab’s existing approved indication, not a new indication). I’ve followed the instruction to build the report around predicted_indications[0] as specified, and flagged this context where relevant so the report isn’t misleading.
Pertuzumab: From HER2-Positive Breast Cancer to Normal Breast-Like Subtype of Breast Carcinoma
One-Sentence Summary
Pertuzumab is a HER2-targeted monoclonal antibody whose approved use is referenced throughout the evidence pack as HER2-positive breast cancer (structured indication/MOA fields are a data gap in this pack). The TxGNN model’s top-ranked prediction is normal breast-like (PAM50 “normal-like”) subtype of breast carcinoma, but 0 of the 6 identified clinical trials specifically enrolled this subtype, and no supporting literature was found — the biological rationale is weak and possibly contradictory to the drug’s mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HER2-positive breast cancer (inferred from evidence annotations; structured license/indication data is a data gap) |
| Predicted New Indication | Normal breast-like subtype of breast carcinoma |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L4 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in this pack). Based on the available context, Pertuzumab is a HER2-targeted monoclonal antibody used in HER2-positive breast cancer, where it blocks HER2 domain II-mediated heterodimerization (notably with HER3), complementing trastuzumab’s mechanism.
The predicted indication, however, raises a biological concern: PAM50 “normal-like” breast carcinoma is a subtype typically characterized as low-proliferation and HER2-negative leaning, which sits awkwardly against an anti-HER2 mechanism of action. This mismatch is explicitly noted in the pack’s own scoring rationale.
Consistent with this concern, all six identified clinical trials are general HER2-positive neoadjuvant treatment studies (T-DXd trials, vaccine combinations, precision-medicine platforms) — none specifically enrolled or stratified for the “normal-like” molecular subtype. The most plausible explanation is that TxGNN’s knowledge-graph embedding over-generalized “breast cancer” trial evidence across molecular subtypes that are not mechanistically interchangeable. This prediction should be treated as hypothesis-generating only, not as an actionable repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05900206 | Phase 2 | Recruiting | 370 | Trastuzumab deruxtecan (T-DXd) vs. standard preoperative treatment in HER2+ breast cancer; biology-driven neoadjuvant selection (ARIADNE) — general HER2+ trial, no normal-like subtype stratification |
| NCT01796197 | Phase 2 | Completed | 23 | Paclitaxel + trastuzumab + pertuzumab as preoperative therapy for inflammatory breast cancer; small sample, general HER2+ population |
| NCT04329065 | Phase 2 | Recruiting | 25 | WOKVAC vaccine combined with neoadjuvant chemotherapy and HER2-targeted therapy; non-subtype-specific |
| NCT05582499 | Phase 2 | Recruiting | 716 | Precision neoadjuvant treatment platform for operable breast cancer; no evidence of subtype-specific stratification |
| NCT04750122 | Phase 1/2 | Recruiting | 46 | Drug-screening (patient-derived tumor-like cell clusters)-guided neoadjuvant therapy for HER2+ early breast cancer |
| NCT06348134 | Phase 2 | Recruiting | 74 | Optimal neoadjuvant-to-adjuvant anti-HER2 therapy in Nigerian women with HER2+ breast cancer |
Note: All six trials were graded “C” relevance (indirect) — none specifically enrolled or reported outcomes for the PAM50 normal-like subtype.
Literature Evidence
Currently no related literature available.
EU Market Information
Pertuzumab is currently not marketed under this evidence pack (0 authorizations on record; no license entries available).
Cytotoxicity
Pertuzumab is a monoclonal antibody targeted therapy used in an oncology context (HER2-positive breast cancer), so this section is included.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (HER2-targeted monoclonal antibody; not a conventional cytotoxic agent) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (normal breast-like subtype) has weak, indirect evidence — no trial or publication specifically supports Pertuzumab’s use in this subtype, and the mechanistic link is biologically questionable given the subtype’s typical HER2-negative leaning. This is best treated as a data-quality/over-generalization artifact of the TxGNN model rather than a genuine repurposing signal.
To proceed, the following is needed:
- Confirmed HER2 amplification/overexpression status specifically within PAM50 “normal-like” tumors, to establish a valid biological rationale
- Core drug-level data gaps must be closed first: original indication/MOA (DG002) and TFDA/EMA label warnings and contraindications (DG001, Blocking)
- If a repurposing signal is still desired, ranks 2–3 in this pack (“progesterone-receptor positive/negative breast cancer”) have substantially stronger evidence (L1, multiple completed Phase 3 RCTs) — but note these represent PR-status stratification within Pertuzumab’s existing HER2-positive breast cancer indication, not a novel indication, and should be labeled accordingly rather than presented as new repurposing candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.